Drug Trial Radar · NCT01140126
Study to Evaluate Safety and Pharmacokinetics of UB-421 Antibody in HIV-1 Infected Adults
Last checked: Nov 19, 2026Latest source record: Jul 11, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
May 2010
Primary completion
Jul 2011
Study completion Jul 2011
Sponsor
- Lead sponsor
- United BiomedicalIndustry
- Sponsor type
- Industry
- First posted
- Jun 9, 2010
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this Phase I study is to determine whether the antibody (UB-421), targeting the HIV-1 receptor on the CD4 molecule (domain 1) of T-lymphocytes and monocytes, is safe and well tolerated when administered to asymptomatic HIV-1 infected adults by intravenous infusion and to assess pharmacokinetic parameters of the antibody in blood and on cells. The neutralizing activity of UB-421 blocks HIV-1 from binding to its receptor on CD4-positive cells; thus, UB-421 functions as an immunotherapeutic intervention to prevent HIV-1 infection.
Conditions
- HIV-1 Infection in Adults (Asymptomatic)
Interventions
Antibody UB-421Drug
Single intravenous infusion at day 0 of a liquid dose of 1, 5, 10 or 25 mg/kg body weight.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate safety and tolerability of a single intravenous infusion at escalating doses of UB-421.Time frame: Screen, treatment & follow-up: 62 to 90 days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Taipei Veterans General Hospital (TVGH)
Taipei, Beitou District, Taiwan
Kaohsiung Veterans General Hospital (KVGH)
Kaohsiung City, Zuoying District, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.